Abstract. Interleukin (IL)-17A is a T helper (Th)17 cell-secreted cytokine that is able to induce various inflammatory responses.
Introduction
Nasopharyngeal carcinoma (NPC) is a common tumor that occurs in the head and neck. NPC is caused by a combination of factors including viral, environmental and heredity reasons (1) (2) (3) (4) (5) . However, its pathogenesis remains unclear. Previous studies have demonstrated that T helper (Th)17 cells and Th17 cell-secreted interleukin (IL)-17A in the tumor microenvironment leads to a significant increase in tumor progression of various types of cancer, including lung, intestinal and brain cancer (6) (7) (8) . Furthermore, it has been reported that exogenous IL-17A may significantly promote cell migration and invasion in NPC cells (9) ; however, the effect of IL-17A on NPC cells and its underlying mechanism remain unclear.
It is well-known that the activation of signaling pathways is involved in various types of carcinoma (10) (11) (12) (13) . Among these, AKT serine/threonine kinase 1 (Akt1) activation has been revealed to serve an essential role in numerous types of carcinoma, including NPC (14) (15) (16) (17) (18) (19) (20) (21) . Thus, targeting aberrant Akt1 signaling may provide an effective and novel strategy for the treatment of patients with NPC. Despite the fact that Akt1 activation is common in NPC, the mechanism of this activation has not been elucidated.
Increasing evidence suggests that modification of protein acetylation is involved in the regulation of various cellular biological events, including cell proliferation, apoptosis, autophagy and inflammatory responses (22) (23) (24) (25) (26) . It has been reported that Akt1 acetylation promotes Akt1 phosphorylation and enhances the proliferation of human glioblastoma cells (27) ; however, the role of Akt1 acetylation in regulating Akt1 activation in NPC remains unclear.
In the current study, the role of IL-17A in the proliferation of human NPC cells was evaluated in vitro. E1A binding protein p300 (p300)-mediated Akt1 acetylation and its role in the regulation of NPC cell proliferation were also investigated. Cell culture. The human NPC cell line C666-1 was obtained from the American Type Culture Collection (Manassas, VA, USA). Cells were cultured in RPMI-1640 medium (Thermo Fisher Scientific, Inc.) supplemented with 10% (v/v) fetal bovine serum from Gibco (Thermo Fisher Scientific, Inc.), 50 U/ml penicillin and 100 ug/ml streptomycin (both Invitrogen; Thermo Fisher Scientific, Inc.) at 37˚C in 5% CO 2 .
Materials and methods

Reagents
Cell treatment and study design. Various doses of purified human IL-17A protein (0, 0.001, 0.01, 0.1, 1, 10 and 100 ng/ml) were added into the culture medium of C666-1 NPC cells. Following 48 h incubation at 37˚C, cellular proliferation was detected using the CCK-8 assay. Next, the cells were incubated with anti-IL-17AR neutralizing antibody (0.01, 0.1 and 1 µg/ml) or iso control IgG (0.01, 0.1 and 1 µg/ml) at 37˚C for 30 min, and subsequently incubated with IL-17A (10 ng/ml) or PBS solvent control at 37˚C for 48 h. Subsequently, cellular proliferation was detected. The levels of Akt1 phosphorylation at Thr308 and Ser473 sites, as well as Akt1 acetylation were detected in C666-1 cells stimulated with IL-17A (10 ng/ml) or PBS solvent control at 37˚C for 30 min. Furthermore, the expression of CBP, p300 and PCAF, as well as the interaction of Akt1 with CBP, p300 and PCAF were detected in C666-1 cells stimulated with IL-17A (10 ng/ml) or PBS solvent control at 37˚C for 30 min. C666-1 cells were transfected with p300 short hairpin (sh)RNA or control shRNA and cultured at 37˚C for 48 h, followed by IL-17A stimulation (10 ng/ml) at 37˚C for 30 min or 48 h. Akt1 acetylation and phosphorylation in C666-1 cells were determined at 30 min following IL-17A stimulation, and cellular proliferation was determined at 48 h following IL-17A stimulation. Finally, Ly294002 (10 µM/ml) or DMSO solvent control were added into the culture medium of C666-1 NPC cells at 30 min prior to IL-17A stimulation (10 ng/ml) and the cellular proliferation was detected at 48 h following IL-17A stimulation.
Generation of overexpression plasmids. The plasmid of pcDNA3.1/Akt1-His was provided by Dr. Lei Shi at The First People's Hospital of Kunshan affiliated to Jiangsu University (Zhenjiang, China).
Construction of (sh)RNA expression plasmids.
To silence the p300 gene in human NPC cells, various shRNA sequences were designed against human p300 mRNA (NM_001429.3) by Shanghai Genkan Biotechnology Co., Ltd. The different DNA segments of p300 shRNA were constructed into the plasmids of pGCsi-U6/neo/GFP respectively by Shanghai Genkan Biotechnology Co., Ltd. and the most effective shRNA expression plasmids (5'-GGA CAG GTA TCA AAT CCT C-3') were selected for further functional experiments.
Cellular transfection. NPC cells were transfected with pcDNA3.1/A kt1-His or pG Csi-U6/neo/GF P usi ng Lipofectamine 2000 according to a previously described method (28) . Cells were seeded into 6-well plates at a density of 1x10 5 cells/well. Following 24 h at 37˚C, 4 µg of plasmid was transfected into each well.
Co-immunoprecipitation experiment. For certain studies, co-immunoprecipitation experiments were performed using an antibody against t-Akt1 according to a previously described method (28) .
Western blot analysis. Western blot analysis was performed to detect β-actin, CBP, p300, PCAF, t-Akt1, p-Akt-Thr 308 , p-Akt-Ser 473 and acetylated-lysine, according to a previously described method (28) .
CCK-8 assay.
Following each treatment, NPC cells were incubated with CCK-8 at 37˚C for 4 h. The formazan product was measured with a microplate reader at a wavelength of 450 nm and the absorbance was directly proportional to the cell number (29) .
Statistical analysis. All statistical analysis was performed using SPSS software (version 11.5; SPSS, Inc., Chicago, IL, USA). All data are presented as the mean ± standard deviation. The statistical significance of groups was evaluated using one-way analysis of variance with simultaneous multiple comparisons between groups using Bonferroni's correction. P<0.05 was considered to indicate a statistically significant difference.
Results
IL-17A promotes the proliferation of human NPC cells.
Various doses of purified human IL-17A protein (0, 0.001, 0.01, 0.1, 1, 10 and 100 ng/ml) were added into the culture medium to induce proliferation of C666-1 NPC cells at 37˚C for 48 hr. The proliferation assay demonstrated that IL-17A enhanced the proliferation of C666-1 cells in a dose-dependent manner (Fig. 1A) . Compared with the untreated control group, the proliferative activity was significantly increased in the C666-1 cells treated with 0.1 ng/ml IL-17. Furthermore, the cells were incubated with anti-IL-17AR neutralizing antibody or IgG iso control at 37˚C for 30 min and subsequently incubated with IL-17A or PBS control at 37˚C for 48 h. The proliferation assay revealed that blockade of the IL-17A receptor significantly reduced IL-17A-triggered C666-1 cell proliferation compared with the isotype IgG control group (Fig. 1B) . These findings indicate that IL-17A is able to promote the proliferation of human NPC cells.
Akt1 phosphorylation and acetylation is enhanced in human NPC cells induced by IL-17A.
Since Akt1 activation is considered to be involved in human NPC cell proliferation (14) (15) (16) (17) , the effect of IL-17A stimulation on Akt1 activation was further investigated in NPC cells. It was demonstrated that the levels of Akt1 phosphorylation at Thr 308 and Ser 473 sites were markedly enhanced in C666-1 cells stimulated by IL-17A for 30 min in vitro compared with the untreated control group (Fig. 2A) . It has been reported that the modification of protein acetylation is an important post-transcriptional regulation that may promote Akt1 phosphorylation (27) . Therefore, the effect of IL-17A stimulation on Akt1 acetylation was studied in C666-1 cells subsequently. The result revealed that the level of Akt1 acetylation was markedly increased in human NPC cells following stimulation with IL-17A for 30 min in vitro compared with the isotype IgG treated control group (Fig. 2B) .
Interaction of p300 with Akt1 is increased in human NPC cells treated with IL-17A. In order to investigate the potential mechanism underlying Akt1 acetylation, the expression of CBP, p300 and PCAF (three important acetyl transferases) (30) (31) (32) and the interaction of Akt1 with CBP, p300 and PCAF at the protein level were detected in C666-1 cells stimulated by IL-17A for 30 min. It was demonstrated that IL-17A did not markedly enhance the lysate protein expression of CBP, p300 and PCAF in C666-1 cells compared with the corresponding untreated control groups (Fig. 3) . However, the interaction of Akt1 with p300, but not with CBP or PCAF at the protein level, was revealed to be markedly enhanced in C666-1 cells in response to IL-17A stimulation compared with the untreated and isotype IgG control groups (Fig. 3) . These results indicate that IL-17A stimulation enhances the interaction of p300 with Akt1 at the protein level in human NPC cells, suggesting a potential role of p300 in acetylating Akt1.
p300 is required for Akt1 acetylation in NPC cells by exposure to IL-17A.
In order to further determine the role of p300 in Akt1 acetylation and phosphorylation, C666-1 cells were treated with shRNA targeted against p300 for 48 h, followed by IL-17A stimulation for 30 min. The co-immunoprecipitation assay demonstrated that the shRNA knockdown of p300 significantly suppressed Akt1 acetylation and phosphorylation in C666-1 cells exposed to IL-17A, compared with the corresponding shRNA control groups (Fig. 4) , suggesting that the acetyltransferase activity of p300 is required for Akt1 acetylation and phosphorylation in NPC cells.
p300-mediated Akt1 acetylation contributes to the proliferation of NPC cells stimulated by IL-17A.
Since p300 was revealed to be required for Akt1 acetylation in NPC cells by exposure to IL-17A (Fig. 4) , the role of p300-mediated Akt1 acetylation in proliferation of NPC cells stimulated by IL-17A was further determined. The results demonstrated that the shRNA knockdown of p300 (Fig. 5A) or the blockade of Akt1 via Ly294002 treatment (Fig. 5B) could cause significant inhibition with regards to cellular proliferation in C666-1 cells treated with IL-17A. Taken together, the data indicate that p300-mediated Akt1 acetylation contribute to the proliferation of NPC cells stimulated by IL-17A.
Discussion
NPC is one of the most common types of malignancy in Southern China and Southeast Asia (1,2). However, the molecular pathogenesis of NPC remains unclear. Recently, inflammatory response has been considered to serve an important role in the process of cancer development (33) (34) (35) (36) . Furthermore, the generation of cytokines, particularly IL-17A, has been demonstrated to serve an essential role in regulating inflammatory responses in vivo (37, 38) and contribute to cancer progression (39, 40 ). In the current study, the effect of IL-17A The data are from one experiment (n=3 in each group), and are representative of three independent experiments. Representative western blot photographs were produced. IL-17A, interleukin-17A; IgG, immunoglobulin G; Ack, acelytated; Akt1, AKT serine/threonine kinase 1; p, phosphorylated; t, total; iso, isotype; IP, immunoprecipitation. The data are from one experiment (n=3 in each group), and are representative of three independent experiments. Representative western blot photographs were produced. IL-17A, interleukin-17A; IgG, immunoglobulin G; CBP, CREB-binding protein; p300, E1A binding protein p300; PCAF, p300/CBP-associated factor; Akt1, AKT serine/threonine kinase 1; iso, isotype; IP, immunoprecipitation.
in the proliferation of human NPC cells was initially evaluated. It was revealed that IL-17A in vitro was able to enhance the proliferation of human NPC cells. Further investigation revealed that blockade of the IL-17A receptor was able to inhibit IL-17A-triggered NPC cell proliferation. These results indicate that an overproduction of IL-17A may contribute to the proliferation of human NPC cells. Notably, Li et al (41) identified that tumor microenvironment macrophage inhibitory factor directs the accumulation of IL-17-producing tumor-infiltrating lymphocytes and predicts favorable survival in patients with NPC. However, the results of the present study suggest that IL-17A directly promotes the proliferation of human NPC cells. One possible explanation is that tumor microenvironment macrophages inhibit NPC growth via other mechanisms, although they may promote the accumulation of IL-17-producing tumor-infiltrating lymphocytes within NPC tumor tissue.
The proliferation of cancer cells is regulated by a complex array of signaling pathways (42, 43) . Among these signaling pathways, the activation of Akt1 is involved in proliferative and anti-apoptotic effects in NPC (44, 45) . Therefore, in the present study, Akt1 phosphorylation was further measured in NPC cells stimulated with IL-17A. The data revealed that Akt1 phosphorylation was increased in NPC cells treated with IL-17A compared with the untreated control group. However, the mechanism underlying the regulation of Akt1 phosphorylation remains elusive. Given that Akt1 is able to undergo acetylation, which is an essential regulatory mehcanism required for Akt phosphorylation and subsequent activation (27) P<0.01 vs. control shRNA+IL-17A group. The data are from one experiment, and are representative of three independent experiments. Results are presented as the mean ± standard deviation (n=3 in each group). Representative western blot photographs were produced. IL-17A, interleukin-17A; IgG, immunoglobulin G; Ack, acelytated; Akt1, AKT serine/threonine kinase 1; p, phosphorylated; t, total; iso, isotype; IP, immunoprecipitation; p300, E1A binding protein p300; sh, short hairpin. .01 vs. DMSO+IL-17A group. The data are from one experiment, and are representative of three independent experiments. Results are presented as the mean ± standard deviation (n=3 in each group). sh, short hairpin; OD, optical density; p300, E1A binding protein p300; DMSO, dimethyl sulfoxide; IL-17A, interleukin-17A; Akt1, AKT serine/threonine kinase 1.
Since Akt1 acetylation was markedly enhanced in human NPC cells treated with IL-17A, further experiments were designed to investigate the mechanism of Akt1 acetylation. It is well accepted that CBP, p300 and PCAF possess acetyl transferase activity and serve direct roles in the regulation of transcription factor and signaling molecule activity (30) (31) (32) . Therefore, the roles of CBP, p300 and PCAF in Akt1 acetylation were investigated in C666-1 cells treated with IL-17A. The results revealed that the interaction of Akt1 with p300, but not CBP and PCAF at the protein level, was enhanced in C666-1 cells in response to IL-17A stimulation. In addition, p300 silencing suppressed Akt1 acetylation and phosphorylation, and the cellular proliferation of NPC cells in response to IL-17A. These results indicate that p300-mediated Akt1 acetylation is important for Akt1 activation and cellular proliferation in human NPC cells induced by IL-17A. Since Akt activation is regulated by a complex mechanism including phosphorylation, ubiquitination, SUMOylation and acetylation (27, 46, 47) , further studies are required to investigate the potential interaction of these modifications in human NPC cells exposed to IL-17A.
In conclusion, the results of the current study revealed that IL-17A could stimulate the proliferation of human NPC cells in vitro. Furthermore, it was demonstrated that p300-mediated Akt1 acetylation was involved in the proliferation of human NPC cells in response to IL-17A. These results may provide a potential strategy for treating patients with NPC through the inhibition of IL-17A or its receptors.
